Table 1.
PHRT (N=15; 11 male, 4 female) |
PHET (N=13; 9 male, 4 female) |
PHTC (N=15; 10 male, 5 female) |
NMTC (N=15; 9 male, 6 female) |
|||||
---|---|---|---|---|---|---|---|---|
Before | After | Before | After | Before | After | Before | After | |
Age, y | 21.1 ± 0.6 | − | 20.1 ± 0.9 | − | 21.6 ± 0.8 | − | 21.6 ± 0.7 | − |
Height, cm | 174.8 ± 2.4 | − | 177.0 ± 2.0 | − | 180.1 ± 2.7 | − | 173.3 ± 2.4 | − |
Weight, kg | 84.2 ± 4.7 | 85.0 ± 4.9 | 86.7 ± 3.6 | 84.1 ± 2.3 | 87.8 ± 4.3 | 88.5 ± 4.6 | 80.9 ± 3.4 | 81.7 ± 3.4 |
BMI, kg/m2 | 27.4 ± 1.3 | 27.5 ± 1.4 | 28.7 ± 1.4 | 28.3 ± 1.6 | 27.0 ± 1.1 | 27.2 ± 1.2 | 24.5 ± 0.9 | 25.6 ± 0.8 |
HR, bpm | 63 ± 3.4 | 61 ± 2.6 | 64 ± 4.4 | 56 ± 3.6 | 60 ± 2.8 | 58 ± 2.9 | 57 ± 2.1 | 58 ± 1.9 |
SBP, mmHg | 130 ± 3* | 121 ± 2*† | 132 ± 3* | 120 ± 2*† | 130 ± 3* | 130 ± 4* | 111 ± 4 | 112 ± 4 |
DBP, mmHg | 80 ± 2* | 72 ± 2*† | 81 ± 1* | 74 ± 2*† | 81 ± 2* | 81 ± 2* | 67 ± 2 | 68 ± 2 |
MAP, mmHg | 94 ± 2* | 85 ± 2† | 94 ± 2* | 86 ± 2† | 95 ± 2* | 94 ± 2* | 80 ± 2 | 81 ± 2 |
fVC, ml/min/100ml/mmHg | 0.029 ± 0.005* | 0.042 ± 0.004† | 0.032 ± 0.003* | 0.039 ± 0.005† | 0.030 ± 0.004* | 0.031 ± 0.003* | 0.039 ± 0.002 | 0.037 ± 0.003 |
cVC, ml/min/100ml/mmHg | 0.024 ± 0.004* | 0.035 ± 0.003† | 0.026 ± 0.004* | 0.038 ± 0.004† | 0.028 ± 0.003* | 0.029 ± 0.004* | 0.036 ± 0.003 | 0.034 ± 0.004 |
Values are mean±SEM. PHRT indicates prehypertensive resistance trained; PHET, prehypertensive endurance trained; PHTC, prehypertensive time control; NMTC, normotensive time control; BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; fVC, forearm vascular conductance; cVC, calf vascular conductance. There were no significant differences between prehypertensive groups at baseline (P>0.05). Significance values are reported from between group and between timepoint repeated measures ANOVA and Tukey post hoc analysis.
P<0.05 versus normotensive control values at same timepoint;
P<0.05 versus pretreatment values.